Biocytogen Pharmaceuticals (Beijing) Co. Ltd. and Abl Bio Inc. have established a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
Kazia Therapeutics Ltd. has out-licensed paxalisib as a potential treatment for intractable epilepsy in focal cortical dysplasia type 2 and tuberous sclerosis complex disease in a carve-out deal with Sovargen Co. Ltd. for $20.5 million plus sales royalties.
Zhejiang Wenda Pharma Technology Ltd. has synthesized poly (ADP-ribose) polymerase-1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of autoimmune disease, cancer and inflammatory disorders.
Humanwell Healthcare (Group) Co. Ltd. has disclosed microtubule destabilizers (tubulin polymerization inhibitors) reported to be useful for the treatment of anemia, asthma, atherosclerosis and rheumatoid arthritis, among others.
Southeast University scientists have reported work leading to the identification of multitargeting histone deacetylase (HDAC) inhibitors as potential anticancer agents.
Cancer Focus Fund LP, an investment fund established in collaboration with The University of Texas MD Anderson Cancer Center, is investing $4.5 million to support a first-in-human trial of Eisbach Bio GmbH’s lead candidate, EIS-12656.
Valirx plc has signed an evaluation agreement with Imperial College London enabling Valirx to evaluate research relating to novel therapeutic candidates for cancer treatment.
Breakpoint Therapeutics GmbH has nominated its first preclinical DNA damage response development candidate, BTX-011, for the treatment of solid tumors. IND-enabling activities have already commenced.
Unc-51-like autophagy-activating kinases 1 and 2 (ULK1/2) are enzymes that play a key role in initiating and regulating autophagy, with ULK1/2 autophagy being an adaptive stress response to multiple cancer therapies, supporting cell proliferation and tumor progression. At the recently concluded ACS meeting in New Orleans, Deciphera Pharmaceuticals LLC presented the discovery of a first-in-class ULK1/2 inhibitor as a potential new anticancer agent.
The Hodgkin lymphoma space found itself in the spotlight late last year when Affimed NV rolled out updated data with lead innate cell engager acimtamig when combined with allogeneic natural killer cells. Findings from the investigator-initiated trial became the topic of talk at the American Society of Hematology meeting, when Yago Nieto, professor at the University of Texas MD Anderson Cancer Center – and principal investigator of the study – spoke.
RSS
